Discovering the Shared and Everlasting
Future of Humans and Animals

ANIMAL HEALTH INNOVATION ASIA | 2019 November 6-7 | Tokyo, JapanANIMAL HEALTH INNOVATION ASIA | 2019 November 6-7 | Tokyo, Japan

ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.

Animals in Japan.

What’s New



Thank you for dropping by the Zenoaq pod at the Animal Health Investment Europe

March 08, 2019

We are very glad to have again had the opportunity of participating at this esteemed event, where we extended successful networking and gained useful market insights into the Animal Health industry. Our sincerest gratitude to all those who spent time with us during the forum. We look forward to meeting you all again in the near future, especially at the Animal Health Innovation Asia forum to be held in Tokyo, Japan on the 6th and 7th of November, 2019.



ZENOAQ Supports Animal Health Innovation Asia 2019 as the Main Sponsor

February 12, 2019

ZENOAQ has been a regular participant at the Animal Health Innovation Asia event since its inception, and is honored to be the Headline Partner for the 2019 event, which will be held in Tokyo on November 6-7.

Animal Health Innovation Asia is a premier B2B conference showcasing emerging animal health and nutrition companies, from Japan and across the Asia-Pacific, that are actively seeking financial investment or strategic partnership conversations with large corporate firms, investment banks and other funding organizations. It provides guidance veterinary market trends, animal health industry dynamics, insight on how emerging companies are using innovations to prevent disease, and market analysis on M&A activities across the animal health and nutrition markets in Asia.

We hope to see you and your team at the forum in November.

For more information, please visit the official site below.
■ Animal Health Innovation Asia 2019 (Tokyo)


Immunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ

February 07, 2019

Immunomic Therapeutics announced today that the company has granted ZENOAQ an exclusive license to develop and commercialize its inestigational DNA vaccine, ITI-002, for canine atopic dermatitis and other companion animal allergies.

Active_73957528_1_ITI_Zenoaq_press release.pdf


ZENOAQ expresses its thoughts and approach during the 3rd AHIA

November 09, 2018

ZENOAQ actively participated in the 3rd annual Animal Health Innovation Asia forum held in Hong Kong and was also a panelist in the panel discussion entitled "Biotech in Japan" hosted by Mr. Joseph Harvey from Animal Pharm far left in the photo. Other panelists were Dr. Mark Micallef (ZENOAQ) from left, Dr. Yuki Ujimasa, President of AHRMS, Inc. and Prof. Takuya Mizuno from Yamaguchi University. During the discussion, ZENOAQ shared its thoughts and approach on the subject of innovation in biotech in Japan. ZENOAQ sincerely thanks all participants in particular those who asked questions, livening up the panel discussion. The discussion showed that there is great interest in the Animal Health Industry in Japan. The next Animal Health Innovation Asia forum will be held in Tokyo, Japan in November 2019 and we hope to see you there.



New York Office Set up

October 01, 2018

Zenoaq is pleased to announce the establishment of its New York branch as of October 1st, 2018. New York office is the 2nd overseas' office for Zenoaq, following the establishment of our Beijing office in 2005.

This is consistent with our intention to expand our presence internationally. In recent years, Zenoaq put biotechnology at the center of its drug discovery development, resulting in our innovative product and the world's first therapeutic product for canine atopic dermatitis applying genetic recombinant technology, "Allermmune® HDM", as well as other pipelines especially in oncology and dermatology. Allermmune® HDM is already commercially available in Japan and South Korea. We look forward to delivering our novel therapeutic solutions to patients around the world in the near future.

With its strategic portfolio, Zenoaq will strive to promote the benefits that animals bring to human beings around the world.

■■Outline of New York office■■
 Name: ZENOAQ New York Branch
 Date of Establishment: October 1, 2018
 Mailing Address: 153 E 110th street #825, New York, NY 10029, USA